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Background: Ameloblastoma (AMB), odontogenic keratocyst (OKC) and adenomatoid odontogenic tumor (AOT) 
are epithelial odontogenic lesions with diverse biologic profiles. Defects in regulation of apoptosis and cell cycle 
may be involved in the development and progression of those lesions, therefore we aimed to investigate the expres-
sion of Bcl-2, Bax and p53 to better understand the possible role of these proteins in AMBs, OKCs and AOTs.
Material and Methods: The studied sample consisted of 20 AMBs, 20 OKCs and 20 AOTs. Immunohistochemistry 
technique was performed for the antibodies p53, Bcl-2 and Bax. Immunoreactivity was observed in the epithelial 
component and positive cells were counted in five fields (100x magnification). Statistical analysis was performed 
with Kruskal-Wallis and Spearman tests (p <0.05). 
Results: All lesions exhibited staining for the three studied proteins. There was no statistically significant associa-
tions between the expression of proteins and the lesions, however we identified a positive correlation between the 
expression of p53 and Bcl-2 (r = 0.200) and a negative correlation between p53 and Bax expressions (r = -0.100). 
In addition, p53 and Bax were similarly expressed between AMBs and OKCs. Bcl-2 was similarly expressed in 
AMBs and AOTs. 
Conclusions: Apoptosis regulatory proteins, as well as cell cycle proteins, are differently expressed in epithelial 
odontogenic lesions and their expression is possibly related to the biological behavior of AMB, OKC and AOT.
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Introduction
The development of the dental organ derives from epi-
thelial cells of the primitive buccal cavity and ectomes-
enchymal cells of the neural crest, which induce the 
formation of ameloblasts and odontoblasts. The rem-
nants from odontogenesis may give rise to the so-called 
odontogenic lesions, including cysts and tumors. Such 
lesions comprise approximately 2.5% of all lesions bi-
opsied in dental offices (1).
The most prevalent odontogenic lesions are benign 
and derived from the odontogenic epithelium. Amelo-
blastoma (AMB) and Odontogenic Keratocyst (OKC) 
are the most common lesions and usually have a more 
aggressive clinical behavior. These lesions are impor-
tant among maxillofacial lesions due to their clinical 
and histological heterogeneity (2). On the other hand, 
Adenomatoid Odontogenic Tumor (AOT) is known for 
its indolent clinical course and no tendency to relapse. 
This morphological and clinical behavior diversity is a 
reflection of the complex development of dental struc-
tures, since odontogenic lesions derive from aberrations 
in odontogenesis (3). 
The growth rate of tissues is determined by proliferative 
activity and cell death. An imbalance between antiapop-
totic proteins, such as Bcl-2 and Bax, can induce dys-
regulation of apoptosis (programmed cell death), which 
may lead to oncogenesis and tumour development. In 
addition, it has been proved that the inactivation of 
genes related to cell cycle regulation, such as p53, con-
fers a selective advantage for tumor development, with 
subsequent impact on cellular activity alterations (4).
To better understand the role of apoptosis and cell pro-
liferation in epithelial odontogenic lesions, we aimed 
to investigate the immunohistochemical expression of 
apoptosis proteins Bax and Bcl-2 and cell cycle protein 
p53 in AMB, OKC and AOT.
Material and Methods
This study was approved by a local Research Ethics 
Committee (protocol number: 1.111.537). 
-Samples
The samples consisted of 60 cases of epithelial odon-
togenic lesions, including 20 AMBs, 20 OKCs and 20 
AOTs. The included AMBs were all multicystic, because 
it is the most common variant and represents the real bio-
logical behavior of this neoplasm. The OKCs associated 
with Nevoid Basal Cell Carcinoma Syndrome (NCBCS) 
were excluded from this study, because of its markedly 
different biologic behavior when compared to those that 
occur in isolated form. Lesions with an important inflam-
matory component were also excluded, since the presence 
of inflammation alters the expression of proteins associ-
ated with cellular proliferation, such as p53.
-Morphological analysis
Morphological analysis was performed on 5μm thick 
sections of paraffin embedded material, stained with 
hematoxylin and eosin (HE) and examined by light mi-
croscopy to reaffirm the histopathologic diagnosis as 
established by WHO (2017) (3).
-Immunohistochemistry
For immunohistochemical analysis, 3µm thick sec-
tions were mounted on organosilane-coated slides 
(3-aminopropyltriethoxsilane; Sigma Chemical Co., St. 
Louis,MO, USA). Antigen retrieval was performed in a 
Pascal pressure cooker with citrate buffer, pH 6.0, for 
three minutes. After treatment with normal serum, the 
sections were incubated with primary antibodies anti-
Bcl-2 (124, Abcam, Cambrigde, MA, U.S.A.), anti-Bax 
(E63, Abcam, Cambrigde, MA, U.S.A.) and anti-p53 
(DO7, Novocastra, Inc, Manhesset, NY, U.S.A) diluted 
respectively in 1:100, 1:500 and 1:1500 for 60 min. Fol-
lowing antigen retrieval, endogenous peroxidase was 
quenched with a 1:1 solution of methanol and 3% hy-
drogen peroxidase. Antibody was detected by immu-
noperoxidase staining using the dextran polymer-based 
signal enhancement technique (ADVANCE™, Dako, 
Carpinteria, CA, USA). For this reaction, diaminoben-
zidine chromogen was used. Negative control consisted 
of bovine serum albumin as replacement for the pri-
mary antibody. Lymphocytes present in the stromal 
tumor area, which have been previously shown to be 
strongly positive for the antibodies anti-Bcl-2, Bax and 
p53, served as internal positive control.
-Immunohistochemical assessment
All slides were examined independently by two observ-
ers. Immunostaining for all studied proteins was ana-
lyzed qualitatively under a light microscope (Olympus 
CH30, Olympus Japan Co., Tokyo, Japan) at a final 
magnification of 400x. Positive staining was defined 
as brown staining of epithelial cells and negative stain-
ing was the complete absence of staining. The staining 
distribution was analyzed semi-quantitatively using the 
following criteria adapted from Lee et al.(5): 0- absence 
of immunostaining; 1- (low) 1 to 10% positive cells; 2- 
(intermediate) 11-50% positive cells; and 3 (high)> 50% 
positive cells. 
-Statistical analysis
For comparisons between protein expressions among 
the lesions, we used Kruskal-Wallis test and Spearman’s 
correlation test. The level of significance considered 
was 5% (P ≤ 0.05). Statistical analyses were performed 
using SPSS software package (IBM Corporation, Ar-
monk, NY, USA).
Results
-Adenomatoid odontogenic tumor 
All studied AOTs showed positive expression for the an-
alyzed proteins (Table 1). This kind of tumor presented 
mostly moderate expression (score 2) for Bcl-2 protein 
(n = 11/55%), which was a predominantly cytoplasmic 






Bcl-2 1 n 7 11 8 26
% 35.0% 55.0% 40.0% 43.3%
2 n 11 7 9 27
% 55.0% 35.0% 45.0% 45.0%
3 n 2 2 3 7
% 10.0% 10.0% 15.0% 11.7%
p53 1 n 18 13 12 43
% 90.0% 65.0% 60.0% 71.7%
2 n 1 7 7 15
% 5.0% 35.0% 35.0% 25.0%
3 n 1 0 1 2
% 5.0% 0.0% 5.0% 3.3%
Bax 1 n 1 6 5 12
% 5.0% 30.0% 25.0% 20.0%
2 n 9 8 7 24
% 45.0% 40.0% 35.0% 40.0%
3 n 10 6 8 24
% 50.0% 30.0% 40.0% 40.0%
Overall n 20 20 20 60
Table 1: Frequency of immunostaining of Bcl-2, p53 and Bax according to the lesions.
AOT: Adenomatoid Odontogenic Tumor; KOT:Keratocystic Odontogenic Tumor; AMB: Ameloblastoma.
and diffuse expression among the tumor cells. The cells 
which form the duct-like structures were often negative 
for Bcl-2 protein (Fig. 1A). p53 showed low expression 
(score 1) (Fig. 1B) in most cases (n = 18/90%). Bax was 
intensely expressed (score 3) in half of the analyzed 
AOTs (n = 10/50%); cells that composed the duct-like 
structures were often immunostained for this protein 
(Fig. 1C).
-Odontogenic keratocyst
All OKCs showed positive expression for the studied 
proteins (Table 1). OKCs presented mainly low expres-
sion (score 1) for the Bcl-2 protein (n = 11/55%). For this 
protein, we observed a cytoplasmic staining extending 
along the basal cell layer of the epithelial lining and 
sometimes to the parabasal cell layer. The cells of the 
upper layers were negative for Bcl-2 (Fig. 1D). Regard-
ing p53, OKCs showed mainly low expression (score 1) 
of this protein (n = 11/55%). p53 was expressed in the 
cytoplasm of the basal cell layer and sometimes in the 
parabasal cell layer. The cells of the upper layers did not 
express p53 (Fig. 1E). OKCs exhibited variable immu-
nostaining for the Bax protein, with a diffuse labeling 
through epithelial layers (Fig. 1F).
-Ameloblastoma
The AMBs were also positive for the studied proteins in 
all analyzed cases (Table 1). The Bcl-2 protein showed 
predominantly moderate (score 2) (n = 9/45%) and low 
(score 1) expression (n = 8/40%); the immunolabeling 
was diffuse and occurred in cylindrical cells on the pe-
riphery of the follicles and epithelial cords (Fig. 1G). 
AMBs showed mainly low (score 1) (n = 16/60%) and 
diffuse immunostaining of p53 protein (Fig. 1H). Bax 
protein showed predominantly intense immunostaining 
(score 3) (n=8/40%), which occurred mainly on the pe-
riphery of epithelial nests (Fig. 1I).
-Statistical analysis
Comparing the immunoexpression of proteins between 
the lesions, we observed no statistically significant dif-
ferences between scores (Table 2). We observed positive 
correlations between Bcl-2 and p53 (r=0.200) and between 
Bcl-2 and Bax (r=0.197), and negative correlation between 
p53 and Bax (r=-0.100), however they were not statistically 
significant (p = 0.126; p = 0.131; p = 0.732, respectively).
Discussion 
Odontogenic lesions are a heterogeneous group of dis-
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Fig. 1: Immunohistochemical expression of Bcl-2, p53 and Bax proteins in AOTs, OKCs and AMBs (IHC, 200X). A) AOT - Immunostaining for 
Bcl-2 protein: positivity in tumor sheets; note that the duct-like cells exhibited no immunostaining for Bcl-2 protein; B) AOT - Immunostaining 
profile for p53 protein: low, diffuse and nuclear; C) AOT - Immunostaining profile for Bax protein: positivity along the duct-like structures. D) 
OKC - Immunostaining for Bcl-2 protein: low, cytoplasmic and diffuse; positive along the basal and parabasal cell layers; E) OKC - Immunos-
taining for p53 protein: note positivity in parabasal stratum and notable absence of marking in the basal cell layer; F) OKC - Immunostaining for 
the Bax protein: intense staining in all epithelial layers. G) AMB - Immunostaining for Bcl-2: positivity along the peripheral layer of the tumor 
follicles; Note that the central cells which resemble stellate reticulum of the enamel organ have no marking; H) AMB - Focal immunostaining 
for p53 protein; I) AMB - Immunostaining for Bax protein: positivity along the peripheral cells of the tumor follicles.
Protein 
Tumor
n Average Median Q25-75 Ranks P
Bcl-2 AOT 20 1.75 2.00 1.00-2.00 32.43  
0.505 KOT 20 1.55 1.00 1.00-2.00 27.13 
AMB 20 1.75 2.00 1.00-2.00 31.95 
      
p53 AOT 20 1.15 1.00 1.00-1.00 25.33  
0.108 
KOT 20 1.35 1.00 1.00-2.00 32.15 
AMB 20 1.45 1.00 1.00-2.00 34.03 
      
Bax AOT 20 2.45 2.50 2.00-3.00 35.60  
0.185 KOT 20 2.00 2.00 1.00-3.00 26.30 
AMB 20 2.15 2.00 1.25-3.00 29.60 
 
Table 2: Evaluation of the differences between the lesions according to Bcl-2, p53 and Bax immunostaining.
AOT: Adenomatoid Odontogenic Tumor; KOT:Keratocystic Odontogenic Tumor; AMB: Ameloblastoma.
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orders that can be classified as hamartomas, cysts or be-
nign and malignant neoplasms, with a quite variable bi-
ological behavior and aggressiveness. Those lesions are 
considered rare and occur only in the maxillary bones, 
arising due to aberrations during the differentiation of 
dental structures. In 2017, the World Health Organiza-
tion (WHO) reclassified the keratocystic odontogenic 
tumor back into the odontogenic cysts category (OKC)
(3), however this is still a controversial matter, since 
85% of OKCs related to the Nevoid basal cell carcinoma 
syndrome (NBCCS) and 30% of non-syndromic cases 
present mutations in the PTCH gene (6). Also, this le-
sion is well known for its aggressiveness and recurrence 
rate after treatment (2). 
The development of odontogenic lesions is related to 
alterations in oncogenes, tumor suppressor genes, on-
coviruses, cell cycle controllers, DNA repair genes, 
apoptosis related elements, among others (7). Tumor 
suppressor genes play a key role in tumor development 
and p53 is one of the most important altered genes in 
oncogenesis since, under normal conditions, its prod-
ucts are responsible for genomic equilibrium through 
induction of apoptosis and cell cycle blocking (8). Like-
wise, oncogenesis involves loss of balance between 
regulators of cell proliferation and apoptosis. Cell death 
by apoptosis plays a key physiological role in tissue de-
velopment and homeostasis, and dysregulation in apop-
tosis is also responsible for events such as carcinogen-
esis, tumor progression and resistance of tumor cells to 
chemotherapy (9). 
In the present study, we observed p53 protein expression 
in all cases of AMBs, OKCs and AOTs. This finding is 
in agreement with Garg et al. (7) who confirmed the 
presence of this protein in several odontogenic lesions, 
including AMBs, ameloblastic carcinomas and amelo-
blastic fibrosarcoma. However, it contrasts with the in-
ferences of Sauk et al. (10), who believe that the expres-
sion of p53 is only an occasional finding in odontogenic 
lesions. Besides, p53 was highly expressed in OKCs 
and AMBs, while AOTs presented predominantly mild 
immunolabeling. Although this was not statistically 
significant, this observation corroborates with the find-
ings of Salehinejad et al. (11), which showed a higher 
positivity index for p53 in AMBs than in AOTs. For this 
reason, we can infer that there is a greater dysregulation 
in cell cycle control in lesions with a more aggressive 
biological behavior, such as AMB and OKC. Still, p53 
protein immunoexpression was similar between AMBs 
and OKCs, which was also previously observed (12). 
This could reinforce the neoplastic phenotype theory in 
OKCs. 
Another differential characteristic of p53 expression 
was its marked presence in the parabasal cell layer of 
OKCs, with evident absence of immunopositivity in the 
basal cell layer. This characteristic was also observed by 
Sajeevan et al. (13) in an evaluation of p53 and PCNA 
expression in OKCs and radicular cysts. On the other 
hand, Deyhimi and Hashemzade (14) found a higher ex-
pression of these proteins in the basal cell layer of OKCs 
and orthokeratinized cysts. The explanation for this fact 
may be related to the lowest stage of differentiation of 
basal cell layer in these lesions, as well as a longer G1 
phase in the parabasal cell layer, which allows a greater 
protein detection (13).
Regarding Bcl-2 and Bax expressions, all cases evalu-
ated showed some degree of immunoreactivity to these 
proteins. This finding was also observed by differ-
ent studies that investigated the imbalance in cellular 
apoptosis in different tumors (15-17). We observed that 
Bcl-2 was similarly expressed in AOTs and AMBs, with 
a score of 2 (moderate) in most of the analyzed cases. 
On the other hand, Razavi et al. (15) reported an in-
creased expression of Bcl-2 and Ki-67 in AMBs when 
compared to AOTs, which could imply less cell cycle 
stability and greater aggressiveness to AMBs, when 
compared to AOTs. Furthermore, we observed reduced 
expression of Bcl-2 in OKCs, compared to AMBs and 
AOTs, which differs from the findings of Amaral et al. 
(18) that demonstrated, through the TUNEL method, 
similar apoptotic index in AMBs and OKCs. The wide 
variety of techniques for evaluating apoptosis as well 
as the diverse immunohistochemical protocols may ex-
plain the differences in these findings. 
Bcl-2 was expressed predominantly in the peripheral 
cells of the follicles and plexiform arrangements of the 
AMBs, corroborating with other findings (19). The ex-
pression of Bcl-2 in the outer layer of AMB cells may 
suggest not only its proliferative activity, but also the 
inhibition of cell death, just as it occurs in the dental 
germ, characteristics that reflect on the growth poten-
tial of this neoplasm (19). Regarding OKCs, Bcl-2 was 
observed mainly in the basal cell layer of the epithelial 
lining, which also has been observed before (16). The 
lack of expression in the upper layers may be due to the 
decrease in the cell ability to divide and to the end of its 
life cycle (16). In addition, this characteristic immuno-
expression may point to the abnormal control of the cell 
cycle in these lesions.
Comparing Bax expression between lesions in AMBs 
and OKCs, we observed quite similar immunostaining. 
This was also reported by Soluk Tekkeşin et al. (4), that 
evaluated the expression of this protein in AMBs, OKCs 
and radicular cysts. Bax was also reported to have in-
creased expression in solid AMBs, when compared to 
the unicystic variant (19). According to the authors, this 
finding could explain the spectrum of biological be-
havior of this lesion. On the other hand, Rangiani and 
Motahhary (20) did not find a statistically significant 
differences in Bax expression between OKCs and or-
thokeratinized odontogenic cysts; The authors suggest 
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that this protein studied alone does not reflect on the 
biological behavior of OKCs.
Moreover, in the present study we identified a positive 
correlation between the expression of p53 and Bcl-2, 
as well as a negative correlation between p53 and Bax, 
although this was not statistically significant. Never-
theless, we can infer that there is an important relation 
between odontogenic lesions that overexpress p53 with 
the increase in antiapoptotic factors expression (Bcl-2), 
as well as a reduction in the expression of pro-apoptotic 
factors (Bax). This could be explained by the fact that 
in normal conditions, p53 contributes to the induction 
of apoptosis, acting directly at the mitochondrial level. 
However, in adverse conditions, such as in neoplasms, 
there is a greater expression of antiapoptotic factors, 
which favors cell survival and escape mechanisms of 
cell cycle control (8).
In conclusion, we observed that apoptosis regulatory 
proteins Bax and Bcl-2 and cell cycle protein p53 are 
differently expressed in the epithelial odontogenic le-
sions AMB, OKC and AOT, which is possibly related 
to their diverse biological behavior. Further investiga-
tion is needed to elucidate the roles of these proteins in 
odontogenesis and development of cystic and neoplastic 
odontogenic lesions. 
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